Indian hepatitis C drug patent decision shakes public health community

On May 9, 2016, the Indian Patent Office granted the US pharmaceutical company Gilead a patent for sofosbuvir, a direct-acting antiviral for the treatment of hepatitis C virus (HCV). 1 The decision to grant the patent reversed an earlier decision by the Indian Patent Office to reject the application...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2016-06, Vol.387 (10035), p.2272-2273
Main Author: t Hoen, Ellen F M
Format: Article
Language:English
Subjects:
Agreements
Antiretroviral drugs
Antiviral agents
Antiviral Agents - economics
Antiviral Agents - therapeutic use
Civil society
Drugs, Generic - economics
Drugs, Generic - therapeutic use
Hepatitis
Hepatitis C
Hepatitis C treatment drugs
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - economics
High income
HIV
Human immunodeficiency virus
Humans
Income
India
Internal Medicine
Patent applications
Patents as Topic
Pharmaceutical industry
Public domain
Public Health
Sofosbuvir - economics
Sofosbuvir - therapeutic use
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On May 9, 2016, the Indian Patent Office granted the US pharmaceutical company Gilead a patent for sofosbuvir, a direct-acting antiviral for the treatment of hepatitis C virus (HCV). 1 The decision to grant the patent reversed an earlier decision by the Indian Patent Office to reject the application after civil society organisations and generic manufacturers had filed a formal opposition to the patent application. 2
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(16)30656-0